Lexatumumab is a monoclonal antibody that targets the death receptor 5 (DR5), which is part of the tumor necrosis factor receptor superfamily. It is designed to induce apoptosis in cancer cells by activating the extrinsic apoptotic pathway. Lexatumumab has been investigated primarily for its potential use in treating various types of cancer, including solid tumors and hematological malignancies. The mechanism of action involves binding to DR5, leading to receptor clustering and subsequent activation of downstream signaling pathways that promote cell death. As a therapeutic agent, Lexatumumab is characterized by its specificity for DR5, which helps minimize effects on normal cells. Clinical studies have explored its efficacy and safety profile, although results may vary based on cancer type and patient characteristics. Like other monoclonal antibodies, Lexatumumab may have side effects, including infusion reactions and potential immune-related effects. Overall, its development reflects ongoing efforts to harness the immune system's capabilities in targeting and eliminating cancer cells.

Lexatumumab

845816-02-6: Immunoglobulin G1, anti-(human cytokine receptor TRAIL-R2) (human monoclonal HGS-ETR2 heavy chain), disulfide with human monoclonal HGS-ETR2 λ-chain, dimer, Lexatumumab, HGS-ETR 2, HGS 1018

A human excitatory monoclonal antibody targeting TRAIL receptor 2.

Lexatumumab (GHS-ETR2), a human antibody, targets TRAILR2 for anticancer effects and apoptosis in mesothelioma.

CAS 845816-02-6: Lexatumumab

Lexatumumab

Ref: 3D-CLA1148

Lexatumumab

Ref: TM-T76815